CEL-SCI (NYSE:CVM) Now Covered by StockNews.com

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research report report published on Friday. The brokerage issued a sell rating on the stock.

CEL-SCI Trading Up 6.1 %

NYSE CVM opened at $0.42 on Friday. CEL-SCI has a 12-month low of $0.36 and a 12-month high of $3.08. The company has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.89. The company has a current ratio of 1.31, a quick ratio of 1.09 and a debt-to-equity ratio of 0.62. The stock has a market cap of $30.76 million, a P/E ratio of -0.81 and a beta of 0.65.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Plotkin Financial Advisors LLC purchased a new position in shares of CEL-SCI during the 3rd quarter valued at about $98,000. Geode Capital Management LLC lifted its holdings in CEL-SCI by 9.6% in the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares during the period. Calton & Associates Inc. purchased a new stake in CEL-SCI in the 3rd quarter worth approximately $50,000. Finally, Renaissance Technologies LLC grew its stake in shares of CEL-SCI by 29.9% during the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after purchasing an additional 40,000 shares during the period. 12.08% of the stock is currently owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.